Yorvipath denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Yorvipath as Duplicate Therapy — and How to Appeal

Yorvipath (palopegteriparatide) is a PTH analog approved for hypoparathyroidism. A duplicate-therapy denial means Humana's system flagged it as therapeutically equivalent to another drug already on the patient's active medication list — most commonly a conventional calcium and active vitamin D supplementation regimen, or potentially another PTH-pathway agent. This denial reason is especially problematic for Yorvipath because the drug's mechanism and FDA-approved indication are specifically intended for patients whose disease is not adequately controlled on conventional replacement therapy, making genuine duplication clinically implausible when the prior agent has failed or is inadequate.

## Why This Is Appealable

A duplicate-therapy flag typically comes from an automated pharmacy benefit management (PBM) rule, not a clinical review. The argument against it is that Yorvipath is not therapeutically interchangeable with conventional calcium/vitamin D supplementation: it replaces the missing hormone rather than compensating downstream for its absence. The treating endocrinologist can document the clinical distinction and the specific ways in which conventional therapy failed to achieve adequate disease control. Humana's own published coverage policy will specify what constitutes a clinically meaningful distinction — your job in the appeal is to map the patient's history directly against that language.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503 (for employer plans), you have the right to a full-and-fair internal review. Submit within the timeframe on the denial notice.
• External review (ACA §2719): If the internal appeal fails, escalate to an independent review organization. The IRO evaluates whether the duplicate-therapy classification is clinically sound. The external review window is typically up to four months from denial. IRO decisions are binding.
• Expedited review: Available when delay would seriously jeopardize health; the insurer and IRO must respond within days.

## Documentation to Gather

1. Diagnosis confirmation — laboratory and clinical records confirming the hypoparathyroidism diagnosis, etiology, and duration. 2. Inadequate-control documentation — chart notes, lab trends, and any records of symptoms (hypocalcemic episodes, hypercalciuria, nephrolithiasis, neuromuscular symptoms) that occurred despite conventional therapy, with dates. 3. Prior-therapy history — complete list of calcium and active vitamin D doses tried, duration, and documented inadequacy or intolerance. 4. Prescriber medical-necessity letter — the endocrinologist should explain the mechanistic difference between Yorvipath and conventional replacement, why the patient's case is not adequately managed by the existing regimen, and why this is not a duplicate. 5. FDA-approved label — cite the indication, which itself references prior treatment context.

## Criteria-Mapping Strategy

Obtain Humana's published coverage policy for Yorvipath and its duplicate-therapy criteria. For each element of the duplicate-therapy determination, provide a one-sentence chart-based rebuttal. Focus especially on mechanism of action differences and the documented inadequacy of any prior agents Humana is treating as equivalent.